Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNTI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSenti strikes up to $40M debt deal with largest shareholder requiring 200% repayment, 54.6% stake
Filed May 1, 2026 · Period ending April 27, 2026 · ~1 min read
Key Changes
-
high
Celadon Partners, Senti's largest shareholder, will acquire 54.6% ownership through $9.7M convertible note purchase, triggering change of control. Second up to $30M tranche contingent on merger deal with CVRs worth up to $60M tied to SENTI-202 milestones.
Item 5.01 verify on EDGAR → -
high
Notes must be repaid at 200% of principal plus interest if not converted within six months. Event of default triggers redemption at 200% or higher based on stock price formula, creating extreme downside risk if company breaches covenants.
Item 1.01 verify on EDGAR → -
high
Full-ratchet anti-dilution protection means any future stock issuance below $0.6261 automatically lowers conversion price, giving noteholder more shares and severely diluting existing shareholders. This is among the most shareholder-unfriendly terms possible.
Item 1.01 verify on EDGAR → -
medium
Shareholder vote required for note issuances beyond exchange cap and potential CVR transaction. Proxy materials will be filed with SEC and mailed to stockholders for approval at annual or special meeting.
Item 8.01 view on EDGAR →
Summary
Senti Biosciences has entered a highly dilutive financing arrangement with Celadon Partners, its largest shareholder, that fundamentally reshapes the company's ownership and financial risk profile. The deal provides up to $40 million in convertible debt but comes with punitive terms: if not converted within six months, Senti must repay 200% of the borrowed amount in cash.
Celadon will immediately control 54.6% of the company upon conversion of the initial $9.7 million tranche, representing a change of control. Retail shareholders face severe dilution risk from the full-ratchet anti-dilution provision, which adjusts the conversion price downward if Senti issues any stock below $0.6261 per share.
This means any future capital raise at a lower price automatically gives Celadon more shares, further diluting existing holders. The second up to $30 million tranche is tied to executing documents for a potential merger where Celadon would acquire the company's operating subsidiary, with shareholders receiving contingent value rights worth up to $60 million based on SENTI-202 clinical and commercial milestones. Investors should watch for the proxy filing detailing the shareholder vote on this transaction and the CVR merger terms. The 200% repayment requirement creates urgent pressure to either convert the debt or complete the merger within six months, suggesting a compressed timeline for a potential change of control that may not maximize shareholder value.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Senti entered a $40M convertible debt deal with its largest shareholder, requiring 200% repayment at maturity and full-ratchet anti-dilution.
Added in current filing · verify on EDGAR →
On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.
The company entered into a securities purchase agreement to issue up to $40 million in convertible notes to an entity affiliated with Celadon Partners, which is the company's largest stockholder. The financing is structured in two tranches: $10 million initially and up to $30 million contingent on executing documents for a potential CVR transaction. The notes are senior secured debt guaranteed by the company and its subsidiaries.
Added in current filing · verify on EDGAR →
On the Maturity Date, if the Notes have not previously been converted or exchanged, Senti Holdings is required to pay the Holder an amount in cash equal to 200% of all outstanding principal and accrued and unpaid interest.
If the notes are not converted or exchanged by the maturity date ($40.0 million, six months after initial closing), the company must pay 200% of the outstanding principal plus interest in cash. This creates significant financial pressure to either convert the debt to equity or complete a transaction within six months, as the company would owe double the borrowed amount.
Added in current filing · verify on EDGAR →
The exchange/conversion price is subject to full-ratchet anti-dilution adjustment if the Company issues or sells its common stock at a price less than the exchange/conversion price then in effect (a “Dilutive Issuance”), in which case the exchange/conversion price shall be reduced to equal the price per share of such Dilutive Issuance.
The notes include full-ratchet anti-dilution protection, meaning if the company issues stock below the $0.6261 conversion price, the noteholder's conversion price automatically adjusts downward to match the lower price. This is highly dilutive to existing shareholders because any future equity raise at a lower price would give the noteholder more shares upon conversion, significantly increasing their ownership percentage.
Added in current filing · verify on EDGAR →
In the case of events of default that relate to bankruptcy, the Company is required to redeem the Notes in cash, and in the case of other events of default, the Holders may require the Company to redeem their Notes in cash. The redemption price is the greater of (i) 200% of the outstanding principal amount of the Notes and (ii) the product of (x) the principal amount being redeemed and (y) the quotient obtained by dividing the greatest closing sale price of the Issuer common stock during the event of default by the lowest exchange price during such period.
Upon an event of default, the company must redeem the notes at the greater of 200% of principal or a formula based on the highest stock price divided by the lowest conversion price during the default period. This creates extreme downside risk for the company if it breaches covenants or experiences financial distress, as it could owe substantially more than 200% of the borrowed amount.
Event · Item 2.03 — Creation of a Direct Financial Obligation
8-K references Item 1.01 for details on a new direct financial obligation, but Item 1.01 text is not included in this filing excerpt.
Added in current filing · verify on EDGAR →
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information contained above in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.
The company disclosed the creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03. The filing cross-references Item 1.01 for substantive details, but that section is not provided in this excerpt. Investors should review the complete 8-K to understand the nature, terms, and materiality of the new obligation.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Senti issued unregistered convertible notes and underlying common stock to an accredited investor under Section 4(a)(2) and Rule 506 exemptions.
Added in current filing · verify on EDGAR →
The Notes and the shares of Company common stock, Senti Biosciences common stock and Senti Holdings common stock underlying the Notes were offered in and are to be issued to the Investor without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a) (2) of the Securities Act of 1933, as amended (the “Securities Act”) as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to one accredited investor, and in reliance on similar exemptions under applicable state laws.
The company issued convertible notes to a single accredited investor without SEC registration, using private placement exemptions. The notes are convertible into common stock of three entities: the Company, Senti Biosciences, and Senti Holdings. This is a private financing transaction that will dilute existing shareholders when the notes convert to equity.
Event · Item 5.01 — Changes in Control of Registrant
Item 5.01 — Changes in Control of Registrant filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Assuming the issuance of the Initial Notes on the date hereof, the Issuance Approval and the immediate exchange of such Notes by Celadon for Company common stock, Celadon would, based on its Schedule 13D/A filed with the SEC on March
31, 2026, beneficially own 54.6% of the Company’s outstanding common stock.
Celadon will beneficially own 54.6% of the Company's outstanding common stock following the issuance and immediate conversion of convertible notes into common stock. This represents a change in control of the Company, as Celadon will hold a majority ownership position.
Added in current filing · verify on EDGAR →
Celadon has agreed to pay an aggregate of $9.7 million for the Initial Notes, and the purchase price is expected to be funded by equity financing by Celadon.
Celadon is purchasing $9.7 million in convertible notes from the Company, with the purchase funded by Celadon's own equity financing. These notes are immediately convertible into common stock, facilitating the change in control transaction.
Event · Item 9.01 — Financial Statements and Exhibits
Senti Biosciences entered a securities purchase agreement for senior secured convertible notes, requiring shareholder approval for issuance beyond exchange cap.
Added in current filing · verify on EDGAR →
Securities Purchase Agreement, dated April 27, 2026, by and among Senti Biosciences Holdings, Inc., Senti Holdings, Inc., Senti Biosciences, Inc. and the purchaser named therein.
The company entered into a securities purchase agreement on April 27, 2026, involving multiple Senti entities and an unnamed purchaser. The agreement relates to senior secured convertible notes issued by Senti Holdings, Inc., with guarantees and registration rights. This represents a financing transaction that will require shareholder approval for note issuances beyond the exchange cap.
Added in current filing · verify on EDGAR →
In connection with the issuance of Notes beyond the Exchange Cap and the potential CVR Transaction (the “Subject Transactions”), the Company intends to file relevant materials with the SEC, including a preliminary proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the proxy materials to each stockholder entitled to vote at the annual of special meeting of stockholders relating to the Subject Transactions.
The company will seek shareholder approval $40.0 million for issuing notes beyond the exchange cap and $10.0 million for a potential CVR (contingent value rights) transaction. A proxy statement will be filed and stockholders will vote at an annual or special meeting. This indicates the financing involves potential dilution significant enough to trigger exchange listing rules requiring shareholder consent.
Added in current filing · verify on EDGAR →
In connection with the issuance of Notes beyond the Exchange Cap and the potential CVR Transaction (the “Subject Transactions”), the Company intends to file relevant materials with the SEC
The filing references a "potential CVR Transaction" alongside the note issuance, though details are not provided. CVRs (contingent value rights) typically provide holders with additional payments contingent on future events. The transaction is described as potential, indicating it may not be finalized, and is subject to shareholder approval.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify